{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:16:09Z","timestamp":1794345369637,"version":"4.9.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["NRF-2023R1A2C2004339"],"award-info":[{"award-number":["NRF-2023R1A2C2004339"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["li.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Laboratory Investigation"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.labinv.2025.104259","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T01:26:45Z","timestamp":1763083605000},"page":"104259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pathologist-Artificial Intelligence Concordance in HER2 Interpretation for Advanced Biliary Tract Cancer: Intraobserver, Interobserver, and Human-Artificial Intelligence Variability"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9322-725X","authenticated-orcid":false,"given":"Hyunchul","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4037-4491","authenticated-orcid":false,"given":"Jinhyung","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3414-9869","authenticated-orcid":false,"given":"Soo Ick","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5177-8937","authenticated-orcid":false,"given":"Beodeul","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1132-5217","authenticated-orcid":false,"given":"Jung Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9780-6155","authenticated-orcid":false,"given":"Chan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Il","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5395-8851","authenticated-orcid":false,"given":"Min Je","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5282-9174","authenticated-orcid":false,"given":"Seok-Pyo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6930-5978","authenticated-orcid":false,"given":"Seok Jeong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4236-5094","authenticated-orcid":false,"given":"Incheon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3365-0096","authenticated-orcid":false,"given":"Sung Hwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0484-6658","authenticated-orcid":false,"given":"Chansik","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungeun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Woo","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0178-9054","authenticated-orcid":false,"given":"Hee Yeon","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9472-0644","authenticated-orcid":false,"given":"Taebum","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanghoon","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3190-9829","authenticated-orcid":false,"given":"Sukjun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heon","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4867-9003","authenticated-orcid":false,"given":"Gwangil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6979-5812","authenticated-orcid":false,"given":"Hong Jae","family":"Chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.labinv.2025.104259_bib1","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.3390\/cancers14071748","article-title":"Evolving role of immunotherapy in advanced biliary tract cancers","volume":"14","author":"Kang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.labinv.2025.104259_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00534-008-0015-0","article-title":"Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan","volume":"16","author":"Miyakawa","year":"2009","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"10.1016\/j.labinv.2025.104259_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107517","article-title":"The choice for the optimal therapy in advanced biliary tract cancers: chemotherapy, targeted therapies or immunotherapy","volume":"210","author":"Palmieri","year":"2020","journal-title":"Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.labinv.2025.104259_bib4","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.labinv.2025.104259_bib5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.labinv.2025.104259_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastasis Rev"},{"issue":"36","key":"10.1016\/j.labinv.2025.104259_bib7","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.23.00606","article-title":"Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-Positive metastatic biliary tract cancer (SGNTUC-019): a phase II basket study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.labinv.2025.104259_bib8","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41467-023-36399-y","article-title":"Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers","volume":"14","author":"Harding","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.labinv.2025.104259_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.labinv.2025.104259_bib10","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1002\/cncr.33102","article-title":"Novel HER2-targeted therapies for HER2-positive metastatic breast cancer","volume":"126","author":"Kunte","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.labinv.2025.104259_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188549","article-title":"HER2-targeted therapies in gastric cancer","volume":"1876","author":"Zhu","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"10.1016\/j.labinv.2025.104259_bib12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.labinv.2025.104259_bib13","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.labinv.2025.104259_bib14","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.labinv.2025.104259_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.labinv.2025.104259_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13058-024-01784-y","article-title":"Augmented interpretation of HER2, ER, and PR in breast cancer by artificial intelligence analyzer: enhancing interobserver agreement through a reader study of 201 cases","volume":"26","author":"Jung","year":"2024","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.labinv.2025.104259_bib17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.breast.2016.09.015","article-title":"Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment","volume":"30","author":"Orlando","year":"2016","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.labinv.2025.104259_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100032","article-title":"Multi-institutional assessment of pathologist scoring HER2 immunohistochemistry","volume":"36","author":"Robbins","year":"2023","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.labinv.2025.104259_bib19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.labinv.2025.104259_bib20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41379-021-00919-2","article-title":"Digital pathology and artificial intelligence in translational medicine and clinical practice","volume":"35","author":"Baxi","year":"2022","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1016\/j.labinv.2025.104259_bib21","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jclinpath-2020-206764","article-title":"Diagnostic concordance and discordance in digital pathology: a systematic review and meta-analysis","volume":"74","author":"Azam","year":"2021","journal-title":"J Clin Pathol"},{"issue":"9","key":"10.1016\/j.labinv.2025.104259_bib22","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1440-1827.2012.02847.x","article-title":"Evaluation of immunohistochemical staining using whole-slide imaging for HER2 scoring of breast cancer in comparison with real glass slides","volume":"62","author":"Kondo","year":"2012","journal-title":"Pathol Int"},{"issue":"4","key":"10.1016\/j.labinv.2025.104259_bib23","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.labinv.2025.104259_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101588","article-title":"Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18","volume":"8","author":"Kim","year":"2023","journal-title":"ESMO Open"},{"issue":"17","key":"10.1016\/j.labinv.2025.104259_bib25","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1016\/j.ejca.2006.06.020","article-title":"High inter-observer agreement in immunohistochemical evaluation of HER-2\/neu expression in breast cancer: a multicentre GEFPICS study","volume":"42","author":"Lacroix-Triki","year":"2006","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.labinv.2025.104259_bib26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1309\/AJCPCX69HGDDGYCQ","article-title":"Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma","volume":"143","author":"Koopman","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"10.1016\/j.labinv.2025.104259_bib27","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1634\/theoncologist.2019-0922","article-title":"HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer","volume":"25","author":"Vivaldi","year":"2020","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.labinv.2025.104259_bib28","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/modpathol.3800774","article-title":"Standardization of HER2 testing: results of an international proficiency-testing ring study","volume":"20","author":"Dowsett","year":"2007","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.labinv.2025.104259_bib29","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1309\/AJCP5UUMFMA5ZKII","article-title":"What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard","volume":"130","author":"Umemura","year":"2008","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"10.1016\/j.labinv.2025.104259_bib30","first-page":"1045","article-title":"Interlaboratory concordance in HER2 testing: Results of a Serbian ring-study","volume":"24","author":"Ivkovic-Kapic","year":"2019","journal-title":"J BUON"},{"key":"10.1016\/j.labinv.2025.104259_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2022.04.011","article-title":"Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response","volume":"170","author":"Choi","year":"2022","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.labinv.2025.104259_bib32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/his.15176","article-title":"An artificial intelligence-powered PD-L1 combined positive score (CPS) analyser in urothelial carcinoma alleviating interobserver and intersite variability","volume":"85","author":"Lee","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.labinv.2025.104259_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA3","article-title":"Trastuzumab deruxtecan (T-DXd) versus treatment of physician\u2019s choice (TPC) in patients (pts) with HER2-low unresectable and\/or metastatic breast cancer (mBC): results of DESTINY-Breast04, a randomized, phase 3 study","volume":"40","author":"Modi","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.labinv.2025.104259_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103679","article-title":"HER2-low gastric cancer: is the subgroup targetable?","volume":"9","author":"Shimozaki","year":"2024","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.labinv.2025.104259_bib35","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.annonc.2023.08.005","article-title":"HER2-low expression in patients with advanced or metastatic solid tumors","volume":"34","author":"Uzunparmak","year":"2023","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.labinv.2025.104259_bib36","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/jcp-2023-208767","article-title":"HER2-low in gastro-oesophageal adenocarcinoma: a real-world pathological perspective","volume":"76","author":"Angerilli","year":"2023","journal-title":"J Clin Pathol"},{"issue":"4","key":"10.1016\/j.labinv.2025.104259_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101582","article-title":"Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric\/gastroesophageal junction adenocarcinoma","volume":"8","author":"Nakayama","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.labinv.2025.104259_bib38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.humpath.2022.05.019","article-title":"Discerning subsets of breast cancer with very low and absent HER2 protein expression","volume":"127","author":"Boyraz","year":"2022","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.labinv.2025.104259_bib39","article-title":"Evaluating low HER2 status in invasive breast carcinoma via HER2 immunohistochemistry, with HER2 FISH correlation: a cohort of 112 patients","volume":"2023","author":"Ardor","year":"2023","journal-title":"Breast J"}],"container-title":["Laboratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683725001692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683725001692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T19:17:28Z","timestamp":1773861448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0023683725001692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0023683725001692"],"URL":"https:\/\/doi.org\/10.1016\/j.labinv.2025.104259","relation":{},"ISSN":["0023-6837"],"issn-type":[{"value":"0023-6837","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathologist-Artificial Intelligence Concordance in HER2 Interpretation for Advanced Biliary Tract Cancer: Intraobserver, Interobserver, and Human-Artificial Intelligence Variability","name":"articletitle","label":"Article Title"},{"value":"Laboratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.labinv.2025.104259","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104259"}}